Currently, there are 104.90M common shares owned by the public and among those 95.70M shares have been available to trade.
The company’s stock has a 5-day price change of -29.28% and -37.23% over the past three months. RVNC shares are trading -53.01% year to date (YTD), with the 12-month market performance down to -30.82% lower. It has a 12-month low price of $2.30 and touched a high of $9.74 over the same period. RVNC has an average intraday trading volume of 4.79 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -21.75%, -25.55%, and -11.20% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Revance Therapeutics Inc (NASDAQ: RVNC) shares accounts for 67.57% of the company’s 104.90M shares outstanding.
It has a market capitalization of $433.24M and a beta (3y monthly) value of 0.82. The earnings-per-share (ttm) stands at -$1.92. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.73% over the week and 6.26% over the month.
Earnings per share for the fiscal year are expected to increase by 45.99%, and 45.20% over the next financial year. EPS should grow at an annualized rate of 11.60% over the next five years, compared to 0.57% over the past 5-year period.
Looking at the support for the RVNC, a number of firms have released research notes about the stock. Mizuho stated their Neutral rating for the stock in a research note on January 29, 2024, with the firm’s price target at $16-$9. Goldman coverage for the Revance Therapeutics Inc (RVNC) stock in a research note released on January 09, 2024 offered a Neutral rating with a price target of $8. Exane BNP Paribas was of a view on August 16, 2023 that the stock is Neutral, while Morgan Stanley gave the stock Equal-Weight rating on October 11, 2022, issuing a price target of $27. Goldman on their part issued Buy rating on September 22, 2022.
